Clinical trials: Lifestyle-Related Condition
Attention-Deficit/Hyperactivity Disorder (ADHD)
Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD
To evaluate the efficacy and safety of NRCT-101SR compared to placebo in subjects 13-17 years of age with ADHD
- Trial name
- ADHD (NCT06215144)
- Testing
- NRCT-101SR
- Where
- 13 sites in United States
- Volunteers
- 95 people
- Sponsor
- Neurocentria, Inc.
Attention Deficit Hyperactivity Disorder
Dasotraline Pediatric ADHD Study
This is a 6 week efficacy and safety study of Dasotraline in subjects 6 to 12 years old with ADHD.
- Trial name
- NCT02428088
- Testing
- Dasotraline
- Where
- 43 sites in United States
- Volunteers
- 330 people
- Sponsor
- Sumitomo Pharma America, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
A Long-term Trial of EB-1020 in Adult Patients With ADHD
The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in patients who have completed the double-blind trial (405-102-00112) conducted in Japan
- Trial name
- NCT06926829
- Testing
- EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg
- Where
- Japan
- Volunteers
- 180 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Physical Inactivity, Psychological Well-Being
VR Exercise Intervention in a Workplace Setting
This research study is designed to better understand how a virtual reality (VR) exercise application may influence overall physical activity and well-being.
- Conditions
- Physical Inactivity, Psychological Well-Being, Work-Related Stress
- Trial name
- VRW (NCT06416839)
- Testing
- VR exercise
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- XRWorkout, Inc
Attention Deficit Hyperactivity Disorder, ADHD
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
This multi-center parallel study is designed to study the efficacy and safety of fixed doses of methylphenidate extended release (ER) capsules of four dose levels compared with a placebo group in pediatric patients with Attention…
- Trial name
- NCT01239030
- Testing
- Methylphenidate Hydrochloride Extended Release Capsules
- Where
- 16 sites in United States
- Volunteers
- 230 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Attention Deficit Disorder With Hyperactivity, Conduct Disorder
Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
The primary objective was to evaluate the safety and tolerability of four doses of SPN-810 in children with ADHD and persistent serious conduct problems.
- Trial name
- NCT00626236
- Testing
- SPN-810
- Where
- 9 sites in United States
- Volunteers
- 78 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Asperger's Syndrome, Dyslexia
My Scrivener® - Measuring Effectiveness and Dose Response in Children
This study will assess whether a computer haptic peripheral device programmed to provide repetitive motion training is as effective as the same repetitive motion training provided by a human being.
- Conditions
- Asperger's Syndrome, Dyslexia, Cerebral Palsy, Attention Deficit Disorder
- Trial name
- NCT00919906
- Testing
- My Scrivener(R)
- Where
- United States
- Volunteers
- 176 people
- Sponsor
- Obslap Research LLC
Attention Deficit Hyperactivity Disorder
A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder
This trial will evaluate the pharmacokinetics, safety, and tolerability of centanafadine in pediatric subjects with ADHD.
- Trial name
- NCT04398225
- Testing
- Centanafadine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy of SPD465 in Adults With ADHD
The purpose of the study is to evaluate how safe and how well SPD465 works compared to placebo in adults with ADHD. It is hypothesized that SPD465 will achieve an extended duration of clinical benefit.
- Trial name
- NCT00202605
- Testing
- Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder (ADHD)
A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions and Their Quality of Life
The main aim of the study is to find out how frequently adults with at least one psychiatric condition have ADHD (but have not been diagnosed with ADHD before) and to describe the quality of life of these adults who have been…
- Trial name
- LANDSCAPE (NCT04943796)
- Where
- 14 sites in Canada, Germany and 4 more
- Volunteers
- 224 people
- Sponsor
- Takeda
Infectious Disease, Neoplasms
AnovaOS Network Powered Patient Registry
The objective of this study is the development, implementation and management of a registry of patient data that captures clinically meaningful, real-world, data on the diagnosis, nature, course of infection, treatment(s) and…
- Conditions
- Infectious Disease, Neoplasms, Diseases of the Blood and Blood-Forming Organs and Certain Disorders Involving the Immune Mechanism (D50-D89), Endocrine, Nutritional and Metabolic Diseases (E00-E89)
- Trial name
- NCT05013944
- Where
- United States
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Anova Enterprises, Inc
Attention Deficit Hyperactivity Disorder, Cannabis Abuse
Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE
The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in adolescents with ADHD and comorbid cannabis abuse.
- Trial name
- PEACE (NCT00687609)
- Testing
- Atomoxetine
- Where
- Netherlands
- Volunteers
- 7 people
- Sponsor
- Eli Lilly and Company